HTG MOLECULAR DIAGNOSTICS, INC. 25,476,989 Shares of Common Stock (par value $0.001 per share) Underwriting AgreementUnderwriting Agreement • September 23rd, 2019 • HTG Molecular Diagnostics, Inc • Laboratory analytical instruments • New York
HTG Molecular Diagnostics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of 25,476,989 shares (the “Shares”) of its common stock, par value $0.001 per share (the “Common Stock”). The 25,476,989 Shares to be sold by the Company are called the “Firm Shares.” In addition, the Company has granted to the Underwriters an option to purchase up to an additional 3,821,548 Shares pursuant to such option are collectively called the “Option Shares.” The Firm Shares and, if and to the extent such option is exercised, the Option Shares, are collectively called the “Offered Shares.” Cantor Fitzgerald & Co. (“CF&Co.”) has agreed to act as representative of the several Underwriters (in such capacity, the “Representative”) in connection with the offering and sale of the Offered Shares. To the extent there are no additional underwriters listed on Schedule A, the term “Representative” as used herei
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • September 23rd, 2019 • HTG Molecular Diagnostics, Inc • Laboratory analytical instruments • New York
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of September 20, 2019 (the “Effective Date”) by and among HTG Molecular Diagnostics, Inc., a Delaware corporation (the “Company”), and each of those persons and entities, severally and not jointly, listed as a Purchaser on the Schedule of Purchasers attached as Schedule I hereto (each a “Purchaser” and together the “Purchasers”). Certain terms used and not otherwise defined in the text of this Agreement are defined in Section 11 hereof.
